The authors report that mesenchymal stem cells isolated from cancers (cancer-derived MSCs, or CA-MSCs) express a broad set of neural-related products. These products encompass multiple categories: neurotrophic factors, neuropeptides, synapse-related proteins, and axon guidance/axogenesis factors. The study emphasizes that CA-MSCs not only produce these neural-related molecules but also exhibit characteristics typical of neural stem cells (NSCs).
Across the examined product classes, the expression profile of CA-MSCs was compared with human NSCs and with MSCs derived from adipose (fat) tissue. The identified neural-related products showed either similar or distinct expression patterns depending on the product class and the cell type being compared. Specific comparative details reported include higher expression of several neurotrophic factors in CA-MSCs relative to NSCs.
CA-MSCs were found to express notably higher levels of neurotrophic factors BDNF, GDNF, and NGF than human NSCs. The prominence of these neurotrophic factors in CA-MSCs is highlighted as a key finding and is presented as a potential mechanism by which CA-MSCs could influence the tumor microenvironment and tumor cell behavior.
Using expression–prognostic analyses based on the neural-related products identified in CA-MSCs, the study reports several associations between gene/protein expression and cancer characteristics or outcomes. Two factors, MDK and MANF, demonstrated higher expression in cancer tissues. Additionally, expression levels of BDNF, NPTX1, and NGF were observed to increase as tumor stage progressed, indicating stage-dependent upregulation for these products.
When ten neuropeptides were examined, their expression levels were generally lower in cancer tissues compared with normal tissues. The study does not provide a full list of the ten neuropeptides within the abstract, but it indicates a consistent trend of reduced neuropeptide expression in cancer in the dataset analyzed.
Thirty synapse-related products were evaluated and shown to have variable expression between cancer and normal tissues. Among this group, SYPL1, SYBP2/3, and STX4 were identified as having significant effects on tumor prognosis. The abstract reports these synapse-related proteins as prognostically relevant, although detailed directionality and numerical effect sizes are not provided in the abstract.
Several axogenesis- or axon guidance–related products were linked to adverse prognosis. Specifically, higher expression of syntaxin-4, neugrin, and additional axogenesis-associated molecules was associated with worse outcomes in cancer. The abstract presents this association as part of a broader pattern implicating neural-related product expression in tumor aggressiveness.
Immunohistochemical analysis reported in the study confirmed that NSC-like CA-MSCs are densely distributed within cancer tissues. In tissue-based assays, these NSC-like CA-MSCs exhibited a clear growth-promoting effect on cancer. The abstract states this observation as supportive evidence that CA-MSCs within the tumor microenvironment can promote tumor growth.
The authors conclude that CA-MSCs, which are abundant in tumors and possess NSC characteristics, express a large repertoire of neural-related products. These molecules include neurotrophic factors that are elevated in CA-MSCs compared with NSCs, neuropeptides that are decreased in cancer, and synapse- and axogenesis-related proteins with variable expression and prognostic associations. Collectively, these findings suggest that nerve-related products derived from CA-MSCs may meaningfully influence tumor progression and patient prognosis.
Notes on methods and data reporting
The abstract summarizes the major findings but does not detail experimental methods, cohort sizes, statistical measures, or the full lists of assessed genes/proteins. Specific quantitative results, methodology, and the full dataset are not reported in the abstract and would need to be consulted in the full article for methodological appraisal and for clinical translation of the reported prognostic associations.